Who are ceftriaxone 1gm for intravenous infusion's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Moxam, Ceftazidim, Rocephin, Zavicefta, Ceftazidime-Avibactam, CREXONT ER, Usual Cefepime Infusion.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ceftriaxone-1gm-for-intravenous-infusion.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

ceftriaxone 1gm for intravenous infusion — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ceftriaxone 1gm for intravenous infusion (ceftriaxone 1gm for intravenous infusion) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cephalosporin antibiotic. Area: Infectious disease.

phase 3 Cephalosporin antibiotic Penicillin-binding protein 1B Infectious disease Small molecule Live · refreshed every 30 min

Target snapshot

ceftriaxone 1gm for intravenous infusion (ceftriaxone 1gm for intravenous infusion) — Ain Shams Maternity Hospital. Ceftriaxone works by inhibiting bacterial cell wall synthesis through inhibition of the enzyme penicillin-binding protein 1B.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ceftriaxone 1gm for intravenous infusion TARGET	ceftriaxone 1gm for intravenous infusion	Ain Shams Maternity Hospital	phase 3	Cephalosporin antibiotic	Penicillin-binding protein 1B
Moxam	latamoxef	Eli Lilly	marketed	latamoxef	Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI
Ceftazidim	Ceftazidim	Tel-Aviv Sourasky Medical Center	marketed		Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI
Rocephin	ceftriaxone	Generic (originally Roche)	marketed	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Zavicefta, Ceftazidime-Avibactam	zavicefta-ceftazidime-avibactam	Pfizer	marketed	Cephalosporin antibiotic and beta-lactamase inhibitor combination	Bacterial cell wall synthesis
CREXONT ER	CREXONT ER	Impax Laboratories, LLC	marketed	First-generation cephalosporin antibiotic	Penicillin-binding proteins (PBPs)
Usual Cefepime Infusion	Usual Cefepime Infusion	Hospital de Clinicas de Porto Alegre	phase 3	Cephalosporin antibiotic	Penicillin-binding proteins (PBPs)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cephalosporin antibiotic class)

Hospital de Clinicas de Porto Alegre · 2 drugs in this class
Ain Shams Maternity Hospital · 1 drug in this class
Arrevus Inc. · 1 drug in this class
Jiangsu Famous Medical Technology Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ceftriaxone 1gm for intravenous infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/ceftriaxone-1gm-for-intravenous-infusion. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab